Author

Publication

2006 - , Ontario

Language

English

Word Count

9,500 words, Guess

Page Count

38 pages

Identifiers

Description

The pharmaceutical market in the United States has been facing a severe problem of raising prices, partially because the granting of weak patents increases the number of patent-based monopolies. This problem was partially addressed by the U.S. Congress through the Hatch-Waxman amendments to the Food, Drug and Cosmetics Act which gave generic applicants bonuses for litigating against pharmaceutical patents, which have been used by these applicants and patentees to enter into exclusionary agreements in exchange for a so-called "reverse" payment.In this thesis I propose a new understanding of Hatch-Waxman as a limitation on patent rights which would not permit agreements including reverse payments, and explain why the focus to fully solve this problem should not be left entirely to courts, but instead should be placed on improving granting of patents.

Subjects

Links

Reader Reviews

No reviews yet for this book.

Be the first to share your thoughts!